Mar. 23 -- FRIDAY, June 22 (HealthDay News) -- A drug derived from the sea squirt showed anti-tumor activity in more than half of 51 patients with a type of cancer called advanced pretreated myxoid ...
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the ...
Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma ...
From May 2011 to June 2020, 101 patients with HG-MLPS were randomly assigned, 45 to the HT arm and 56 to the S arm. The median follow-up was 66 months (IQR, 37-89). Median size was 107 mm (IQR, 84-143 ...
While U.S. Army Staff Sgt. Rayshaun Smith served a tour of duty in South Korea in 2018, he started feeling mild knee pain. At first, he thought it was just from his rigorous military lifestyle or his ...
Medigene AG has selected initial clinical indications for its lead candidate, MDG-1015, specifically gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra ®, also known as afami-cel) for the treatment of adults with a ...
Sarcoma cancer is a rare but aggressive type of cancer that develops in the connective tissues of the body. While it accounts for only 1% of all cancers, it can be more common in children and young ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback